| Title |
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cell lung cancer patients and is reversed by STAT3 knockdown
|
|---|---|
| Published in |
Cancer Discovery, July 2021
|
| DOI | 10.1158/2159-8290.cd-20-1543 |
| Pubmed ID | |
| Authors |
Nabendu Pore, Song Wu, Nathan Standifer, Maria Jure-Kunkel, Melissa de Los Reyes, Yashaswi Shrestha, Rebecca Halpin, Raymond Rothstein, Kathy Mulgrew, Stephen Blackmore, Philip Martin, John Meekin, Matthew Griffin, Ina Bisha, Theresa A Proia, Ricardo J Miragaia, Ronald Herbst, Ashok Gupta, Shaad E Abdullah, Rajiv Raja, Melanie M Frigault, J Carl Barrett, Phillip A Dennis, Maria Libera Ascierto, Michael D Oberst |
X Demographics
The data shown below were collected from the profiles of 69 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 14 | 20% |
| Italy | 6 | 9% |
| France | 3 | 4% |
| Spain | 3 | 4% |
| Switzerland | 2 | 3% |
| Colombia | 2 | 3% |
| United Kingdom | 2 | 3% |
| Ireland | 2 | 3% |
| Japan | 1 | 1% |
| Other | 6 | 9% |
| Unknown | 28 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 32 | 46% |
| Scientists | 25 | 36% |
| Practitioners (doctors, other healthcare professionals) | 9 | 13% |
| Science communicators (journalists, bloggers, editors) | 3 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 18% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Doctoral Student | 2 | 5% |
| Other | 2 | 5% |
| Student > Master | 2 | 5% |
| Other | 5 | 11% |
| Unknown | 20 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 12 | 27% |
| Medicine and Dentistry | 7 | 16% |
| Agricultural and Biological Sciences | 2 | 5% |
| Immunology and Microbiology | 2 | 5% |
| Unspecified | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 20 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 84. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2024.
All research outputs
#509,942
of 25,628,260 outputs
Outputs from Cancer Discovery
#263
of 4,087 outputs
Outputs of similar age
#13,537
of 451,557 outputs
Outputs of similar age from Cancer Discovery
#15
of 94 outputs
Altmetric has tracked 25,628,260 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,087 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.9. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,557 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.